Jacobs Levy Equity Management
CASI

Jacobs Levy Equity Management’s CASI Pharmaceuticals CASI Stock Holding History

Jacobs Levy Equity Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-167,715
Closed -$1.34M – 1004
2021
Q4 		$1.34M Buy
167,715
+94,676
+130% +$943K 0.01% 691
2021
Q3 		$869K Buy
+73,039
New +$988K 0.01% 773

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management's CASI Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of CASI Pharmaceuticals (CASI) in Q1 2022, closing a stake of 167,715 shares — an estimated $1.34M sold.

Jacobs Levy Equity Management first reported a position in CASI in Q3 2021 and held it in 2 quarters. The position peaked at $1.34M in Q4 2021. 44 funds tracked by Wall St. Rank hold CASI as of Q1 2022.

  • Jacobs Levy Equity Management reported no remaining CASI Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 167,715 CASI Pharmaceuticals shares in Q1 2022, an estimated $1.34M.
  • Jacobs Levy Equity Management first reported a position in CASI Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Jacobs Levy Equity Management's CASI Pharmaceuticals position peaked at $1.34M in Q4 2021.
  • 44 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.